製品番号: HY-100950

ABC1183

カスタマーレビュー

Based on 1 Customer Validation

ABC1183 is an orally active selective dual GSK3 and CDK9 inhibitor. ABC1183 inhibits GSK3β, GSK3α and CDK9/cyclin T1 with the IC₅₀ values of 657 nM, 327 nM and 321 nM, respectively. ABC1183 has anti-inflammatory and anti-tumor activities.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.62%
CAS 番号: 1042735-18-1
分子式: C₁₈H₁₄N₄OS
分子量:334.39

保管条件:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

ABC1183 構造式

CAS 番号: 1042735-18-1

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- 体外実験
- 体内実験
化学情報
溶剤 & 溶解度
- 体外
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

IC₅₀ & Target^[1]

CDK9- Cyclin T1

321 nM (IC₅₀)

GSK-3α

327 nM (IC₅₀)

GSK-3β

657 nM (IC₅₀)

GSK-3 アイソフォーム固有の製品をすべて表示 :

CDK アイソフォーム固有の製品をすべて表示 :

体外実験

ABC1183 (3 μM, 24 h) can block cell cycle progression and thus affect cell proliferation^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cycle Analysis^[1]

Cell Line:

LNCaP human prostate cancer cells
Concentration:

3 μM
Incubation Time:

24 hours
Result:

Significantly reduced cells in the G1 and S phases and increased cells in the G2/M and sub-G1 cycle phases.

体内実験

ABC1183 (oral gavage, 5 or 50 mg/kg) inhibits tumor proliferation through negative regulation of cell growth and pro-inflammatory signalling in male C57BL/6 mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male C57BL/6 mice with melanoma B16^[1]
Dosage:

5 mg/kg
Administration:

Oral gavage; 5 times per week; 22 days
Result:

Reduced tumor size and no observed toxicity.
Decreased the expression levels of GSK3 α /β, pSer21/9 and GS pSer641 but no change of total GS expression.

Animal Model:

Male C57BL/6 mice infected crohn’s disease^[1]
Dosage:

50 mg/kg
Administration:

Oral gavage; everyday; 3 days
Result:

Reduced TNF-α by 65%, IL-6 by 30% and IL-1β by 45%.

Animal Model:

Male C57BL/6 mice with ulcerative colitis^[1]
Dosage:

50 mg/kg
Administration:

Oral gavage; once daily; 6 days
Result:

Increased the expression of the anti-inflammatory factor IL-10, while decreasing the pro-inflammatory factor IL-6.

化学情報

CAS 番号 1042735-18-1
性状 Solid
分子量 334.39
分子式 C₁₈H₁₄N₄OS
Color Light yellow to yellow
SMILES

N#CC1=CC=C(C(C2=C(N)N=C(NC3=CC=C(C)C=C3)S2)=O)C=C1
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶剤 & 溶解度

体外:

DMSO : 125 mg/mL (373.82 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.9905 mL

14.9526 mL

29.9052 mL

5 mM

0.5981 mL

2.9905 mL

5.9810 mL

10 mM

0.2991 mL

1.4953 mL

2.9905 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (276 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Randy S Schrecengost，et al. In Vitro and In Vivo Antitumor and Anti-Inflammatory Capabilities of the Novel GSK3 and CDK9 Inhibitor ABC1183. J Pharmacol Exp Ther. 2018 Apr;365(1):107-116. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.9905 mL	14.9526 mL	29.9052 mL	74.7630 mL
	5 mM	0.5981 mL	2.9905 mL	5.9810 mL	14.9526 mL
	10 mM	0.2991 mL	1.4953 mL	2.9905 mL	7.4763 mL
	15 mM	0.1994 mL	0.9968 mL	1.9937 mL	4.9842 mL
	20 mM	0.1495 mL	0.7476 mL	1.4953 mL	3.7381 mL
	25 mM	0.1196 mL	0.5981 mL	1.1962 mL	2.9905 mL
	30 mM	0.0997 mL	0.4984 mL	0.9968 mL	2.4921 mL
	40 mM	0.0748 mL	0.3738 mL	0.7476 mL	1.8691 mL
	50 mM	0.0598 mL	0.2991 mL	0.5981 mL	1.4953 mL
	60 mM	0.0498 mL	0.2492 mL	0.4984 mL	1.2460 mL
	80 mM	0.0374 mL	0.1869 mL	0.3738 mL	0.9345 mL
	100 mM	0.0299 mL	0.1495 mL	0.2991 mL	0.7476 mL

Keywords

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

ABC1183

Cell Cycle/DNA Damage Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

PI3K/Akt/mTOR Compound Library

Protein Tyrosine Kinase Compound Library

Stem Cell Signaling Compound Library

Wnt/Hedgehog/Notch Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Anti-Alzheimer's Disease Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Glucose Metabolism Compound Library

Antidepressant Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Metabolic Enzyme Compound Library

Highly Selective Inhibitors Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Protein Kinase Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

High-Efficiency Gene Editing Compound Library

GSK-3 アイソフォーム固有の製品をすべて表示

CDK アイソフォーム固有の製品をすべて表示

生物活性

化学情報

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

ABC1183 関連分類

HY-100950 関連分類